Kalydeco® (ivacaftor) – Expanded indication
May 17, 2017 – The FDA announced the approval of Vertex’s Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.
Top